Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

NCT03295981 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-04-22

No results posted yet for this study

Summary

The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.

Conditions

  • Giant Cell Tumor of Bone

Interventions

DRUG

Zoledronic Acid

4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement

Sponsors & Collaborators

  • Orthopedic Research and Education Foundation

    collaborator OTHER
  • Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

    collaborator OTHER
  • University of Iowa

    collaborator OTHER
  • Johns Hopkins University

    collaborator OTHER
  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    collaborator OTHER
  • The Cleveland Clinic

    collaborator OTHER
  • Wake Forest University

    collaborator OTHER
  • University of Kansas

    collaborator OTHER
  • Indiana University

    collaborator OTHER
  • University of Oklahoma

    collaborator OTHER
  • Beth Israel Deaconess Medical Center

    collaborator OTHER
  • Boston Children's Hospital

    collaborator OTHER
  • American Academy of Orthopaedic Surgeons

    collaborator OTHER
  • Massachusetts General Hospital

    collaborator OTHER
  • All India Institute of Medical Sciences

    collaborator OTHER
  • University of Washington

    collaborator OTHER
  • University of California

    collaborator OTHER
  • St. Louis University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-03
Primary Completion
2027-01-31
Completion
2028-01-31
FDA Drug
Yes

Countries

  • United States
  • Canada
  • India

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03295981 on ClinicalTrials.gov